Strategies for Browning Agent Delivery
- PMID: 34398404
- DOI: 10.1007/s11095-021-03081-1
Strategies for Browning Agent Delivery
Abstract
Obesity expands as a global climbing epidemic that is often correlated to cardiovascular diseases and endocrine disorders. Converting white adipocytes to brown adipocytes for enhanced energy expenditure has recently emerged as a promising anti-obesity treatment. However, the conventional approaches to apply browning agents systematically suffer from off-target effects, multiple dosage requirements, and poor patient compliance. To date, various delivery strategies have been reported to deliver browning agents for obesity treatment in a safer and more controllable manner. This review will discuss the latest designs in browning agent delivery systems with a focus on nanomedicines and transdermal patches.
Keywords: adipocyte; browning agent; drug delivery; nanoparticle; transdermal patch.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Trigonelline induces browning in 3T3-L1 white adipocytes.Phytother Res. 2021 Feb;35(2):1113-1124. doi: 10.1002/ptr.6892. Epub 2020 Oct 5. Phytother Res. 2021. PMID: 33015893
-
The colorful versatility of adipocytes: white-to-brown transdifferentiation and its therapeutic potential in humans.FEBS J. 2021 Jun;288(12):3628-3646. doi: 10.1111/febs.15470. Epub 2020 Jul 22. FEBS J. 2021. PMID: 32621398 Review.
-
Locally Induced Adipose Tissue Browning by Microneedle Patch for Obesity Treatment.ACS Nano. 2017 Sep 26;11(9):9223-9230. doi: 10.1021/acsnano.7b04348. Epub 2017 Sep 15. ACS Nano. 2017. PMID: 28914527 Free PMC article.
-
Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.Oncotarget. 2016 Dec 6;7(49):81077-81089. doi: 10.18632/oncotarget.13189. Oncotarget. 2016. PMID: 27835589 Free PMC article.
-
Brown, beige, and white: the new color code of fat and its pharmacological implications.Annu Rev Pharmacol Toxicol. 2015;55:207-27. doi: 10.1146/annurev-pharmtox-010814-124346. Epub 2014 Aug 21. Annu Rev Pharmacol Toxicol. 2015. PMID: 25149919 Review.
Cited by
-
Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges.Pharmaceutics. 2023 Nov 16;15(11):2635. doi: 10.3390/pharmaceutics15112635. Pharmaceutics. 2023. PMID: 38004612 Free PMC article. Review.
-
Biomaterial-Based Therapeutic Strategies for Obesity and Its Comorbidities.Pharmaceutics. 2022 Jul 11;14(7):1445. doi: 10.3390/pharmaceutics14071445. Pharmaceutics. 2022. PMID: 35890340 Free PMC article. Review.
-
Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.Int J Mol Sci. 2021 Nov 25;22(23):12754. doi: 10.3390/ijms222312754. Int J Mol Sci. 2021. PMID: 34884558 Free PMC article. Review.
References
-
- GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources